Haematology

Prof. Dr. Mehmet Hilmi Doğu

Doctor and researcher Liv Hospital BahçeşehirLiv Hospital Ulus İstanbul
COVID-19Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseLeukemia, Myeloid, AcuteHodgkin DiseaseMultiple MyelomaLymphoma, Non-HodgkinPneumonia, ViralCoronavirus InfectionsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphoma, T-Cell, Peripheral

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • COVID-19 6 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Leukemia, Lymphocytic, Chronic, B-Cell 5 publications
  • Lymphoma, Large B-Cell, Diffuse 5 publications
  • Leukemia, Myeloid, Acute 4 publications
  • Hodgkin Disease 4 publications
  • Multiple Myeloma 3 publications
  • Lymphoma, Non-Hodgkin 2 publications
  • Pneumonia, Viral 2 publications
  • Coronavirus Infections 2 publications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 publications
  • Lymphoma, T-Cell, Peripheral 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: livhospital.com.

  • Lenfomalar (Hodgkin ve Non-Hodgkin Lenfomalar)
  • Multiple Myeloma ve Plazma hücre hastalıkları
  • Akut Lösemiler ( Akut Myeloblastik Lösemi / Akut Lenfoblastik Lösemi)
  • Kronik Lösemiler (Kronik Lenfositer Lösemi/Kronik Myeloid Lösemi)
  • Kronik Myeloproliferatif Hastalıklar (Polistemia Vera, Esansiyel Trombositoz, Myelofibrozis)

CV

Education and experience

From source

Experience

  • 2015Selçuk Üniversitesi Tıp Fakültesi Hastanesilivhospital.com
  • 2016-2011Pamukkle Üniversitesi İç Hastalıkları Uzmanlık Eğitimilivhospital.com
  • 2011-2011Denizli Sarayköy Devlet Hastanesilivhospital.com
  • 2011-2014Pamukkle Üniversitesi Hematoloji Yandal Uzmanlık Eğitimilivhospital.com
  • 2015-2020İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Kliniği Uzman Doktorlivhospital.com
  • 2015-2020İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Kliniği İdari Sorumlusulivhospital.com
  • 2019-2020İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Kliniği İdari Sorumlu/ Eğitim Görevlisilivhospital.com
  • 2020-2020İstanbul Başakşehir Çam ve Sakura Şehir Hastanesi Hematoloji Kliniği Eğitim Görevlisilivhospital.com

Education

  • 1999-2005Ege Üniversitesi Tıp Fakültesi Tıp Doktorulivhospital.com
  • 2006-2011Pamukkale Üniversitesi İç Hastalıkları Uzmanılivhospital.com
  • 2011-2014Pamukkale Üniversitesi Hematoloji Uzmanılivhospital.com
  • 2014ESCCA Summer School On Cytometry/PRAG (Mayıslivhospital.com
  • 2018İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Doçentlivhospital.com

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyHaematologylivhospital.comFrom source
  • InstitutionLiv Hospital Bahçeşehir, Liv Hospital Uluslivhospital.comFrom source
  • Area of workCOVID-19Extracted from 6 publications · Model version —From source
  • Publications125 publicationsORCID, OpenAlexFrom source
  • ORCID0000-0001-7237-2637ORCIDFrom source
  • Last synchronised4 November 2026 20:55https://www.livhospital.com/prof-dr-mehmet-hilmi-dogulivhospital.com

Scientific work

Publications on COVID-19

125 publications
Publications by year Most: 21, in 2021
  1. 2011: 1 publication
  2. 2012: 4 publications
  3. 2013: 2 publications
  4. 2014: 9 publications
  5. 2015: 17 publications
  6. 2016: 15 publications
  7. 2017: 8 publications
  8. 2018: 5 publications
  9. 2019: 10 publications
  10. 2020: 15 publications
  11. 2021: 21 publications
  12. 2022: 7 publications
  13. 2023: 5 publications
  14. 2024: 2 publications
  15. 2025: 3 publications
  16. 2026: 1 publication
  1. VEXAS Syndrome and IgG4-Related Disease: Coincidental Association or Pathogenetic Link?

    Mediterranean journal of rheumatology, 2026

    DOI 10.31138/mjr.230126.epr PMID 42100070 Open-access full textSource: ORCID

  2. Follicular Lymphoma: Frequency and Timing of Treatment: Single Center Experience

    Istanbul Medical Journal, 2025

    DOI 10.4274/imj.galenos.2025.20788 Open-access full textSource: OpenAlex

  3. Evaluation of The Relationship Between Bone Marrow Changes and Hemogram Findings in HIV-Positive Patients

    Namık Kemal Tıp Dergisi, 2025

    DOI 10.4274/nkmj.galenos.2025.29494 Open-access full textSource: OpenAlex

  4. Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety

    Indian Journal of Hematology and Blood Transfusion, 2025

    DOI 10.1007/s12288-025-02093-w PMID 42040698 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  5. Acinetobacter baumannii in Hematology Practice: Clinical Factors Affecting the Course of Infection

    Acta haematologica oncologica Turcica., 2024

    DOI 10.4274/ahot.galenos.2024.2024-9-3 Open-access full textSource: OpenAlex

  6. Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

    Hitit Medical Journal, 2024

    DOI 10.52827/hititmedj.1320606 Open-access full textSource: OpenAlex

  7. A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

    Istanbul Medical Journal, 2023

    DOI 10.4274/imj.galenos.2023.66742 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  8. AAT: does it have a place in acute leukemia?

    Biomarkers in Medicine, 2023

    DOI 10.2217/bmm-2023-0415 PMID 38197403 Source: ORCID

  9. Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results

    Mediterranean Journal of Hematology and Infectious Diseases, 2023

    DOI 10.4084/mjhid.2023.031 PMID 37180209 4 citations (Europe PMC) Open-access full textSource: ORCID

  10. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

    Journal of Chemotherapy, 2023

    DOI 10.1080/1120009x.2023.2208439 PMID 37211906 3 citations (Europe PMC) Source: ORCID

View all 125 publications